Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8734436 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1RAB9ACNR1CNR2 | |
| SCHEMBL5023004 | 0.89 | CHRM2 (0.39) | CHRM2KIF11KCNH2ACHESLC7A5 | |
| SCHEMBL9068005 | 0.84 | L3MBTL1 (0.37) | SMN1; SMN2NPC1RAB9ANFE2L2 | |
| SCHEMBL9261650 | 0.84 | TAS1R3 (0.36) | CHRM2KCNH2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10586377 | 0.81 | TAAR1 (0.38) | KIF11KCNH2SMN1; SMN2TAAR1NR3C2 | |
| SCHEMBL5023008 | 0.79 | KIF11 (0.56) | KIF11KCNH2SLC7A5 | |
| SCHEMBL8729134 | 0.78 | NFE2L2 (0.41) | SMN1; SMN2NPC1RAB9ANFE2L2 | |
| SCHEMBL8734430 | 0.78 | NR3C2 (0.37) | SMN1; SMN2NR3C2 | |
| SCHEMBL5022963 | 0.77 | KIF11 (0.36) | CHRM2KIF11KCNH2ACHESLC7A5 | |
| SCHEMBL9559238 | 0.77 | NFE2L2 (0.34) | KIF11SMN1; SMN2NPC1RAB9ANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991552-A2 | PHOSPHONYLATED FLUORESCENT DYES AND CONJUGATES | Epoch Biosciences, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7329515-B2 | Solid support for the synthesis of 3′-amino oligonucleotides | SIGMA-ALDRICH CO. (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007098182-A2 | PHOSPHONYLATED FLUORESCENT DYES AND CONJUGATES | EPOCH BIOSCIENCES, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1781675-A2 | PHOSPHONATE FLUORESCENT DYES AND CONJUGATES | Epoch Biosciences, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006020947-A2 | PHOSPHONATE FLUORESCENT DYES AND CONJUGATES | EPOCH BIOSCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PROLIGO LLC (US) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PCNA, DERA, RNGTT | CHRM2 3932/4885KIF11 3018/4885KCNH2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.